Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Since Bernard Rav­ina’s med­ical train­ing in neu­rol­o­gy in the 1990s, there have been few new ther­a­pies that treat a move­ment dis­or­der known as dys­to­nia. … ...

Ei­sai and Mer­ck suc­ceed­ed in stop­ping Shilpa Medicare Ltd. from launch­ing a gener­ic ver­sion of Lenvi­ma for at least an­oth­er decade, Ei­sai said Thurs­day. … ...

The US Supreme Court will con­tin­ue de­cid­ing whether to take up a piv­otal case on state PBM reg­u­la­tion af­ter the fed­er­al gov­ern­ment of­fered its stance … ...

Pep­Gen is aban­don­ing its ex­on 51-skip­ping Duchenne mus­cu­lar dy­s­tro­phy can­di­date af­ter it failed a Phase 2 tri­al. And it is get­ting out of the dis­ease … ...